Buyers widening their own doors: demand already secured, far-side receiving constraint now being cleared
The model's full reasoning — Q3 2023 call → NOWe need to determine if the transcript conveys a situation where demand is real and in hand, the constraint is on the receiving side, and the counterparties are clearing that constraint now, with business ahead. Let's analyze the transcript. Key points: - The company has regulatory approvals in various countries, and is expanding distribution. They mention new distributor in Portugal, first procedure in India, etc. - They talk about independent studies and growing interest. - They mention that in the U.S., they appointed a new VP of sales, and that upon successful outcome of trial and regulatory strategy, they will realize the market opportunity. That suggests the U.S. market is not yet fully realized due to regulatory issues. - They talk about the FDA appeal, and that the De Novo denial doesn't affect other indications. - They mention that in China, they are exploring, achieving coding and reimbursement, and starting penetration. That suggests they are still in early stages. - In Japan, Terumo is working to get regulatory approval, and as soon as they get it, they will start to sell. Meanwhile, IceCure sells directly under doctor importation license. So the constraint is Terumo's regulatory approval, which is on the receiving side? Actually, Terumo is the distributor, and they need regulatory approval to sell. That is a receiving-side constraint? But it's about the distributor's ability to get approval, not about the company's own capacity. However, the company is selling directly in the meantime. - The question asks: does management convey that the company already has business or demand that is secured or already arriving, but the thing standing between the company and a meaningfully larger level of delivered business is the counterparties' own ability to receive, install, qualify, stock, staff, certify, onboard, or absorb it - and does management describe those counterparties as already working on that receiving-side preparation, with the associated business mostly still ahead of the reported results? We need to see if there is a specific situation where demand is in hand, but the constraint is the counterparty's readiness, and they are working on it.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
MKC · Q2 2018 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive, install, etc., and those counterpartie...**NO** The transcript describes a situation where McCormick has already won shelf-space changes and distribution improvements from retailers (customers have accepted the recommendations), but implementation is delayed due to retailers' own operational reset windows and competitor product sell-through. This is framed as a temporary, ongoing industry practice rather than a binding constraint being actively cleared right now to unlock a meaningfully larger volume of already-secured business. Management presents it as part of their category-management progress with runway ahead, not as counterparties clearing a receiving-side bottleneck that is already underway and will drive the bulk of the upside.
BIIB · Q2 2017 → YESThe question is about whether management conveys that they already have secured demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties are already ...YES The transcript shows management conveying exactly this situation for SPINRAZA. Demand is already secured and arriving: “significant uptake in the U.S.” with “strong demand across patient types” and “roughly two third of patients treated to date having Type 2 or Type 3 SMA.” The binding constraint is on 60% of Type 2 patients who have had spinal surgery, creating intrathecal administration challenges on the receiving side.
BXP · Q1 2022 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties ...YES The transcript shows management conveying secured demand through signed leases totaling over 975,000 square feet on vacant space that have not yet commenced occupancy, plus an additional 1.3 million square feet in active negotiations and over 750,000 square feet in the development pipeline.